Over the last 12 months, two Edesa Biotech, Inc. corporate insiders picked up shares at market prices, about $233,000 in total, and none of them sold.
Biggest single buyer: Nijhawan Pardeep, CEO, with roughly $67,000. C-suite participation is part of the picture here.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 33 investment managers listed EDSA in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Brooks Michael J | President | Buy | 2,000 | $1.57 | $3K | SEC |
| Mar 10, 2026 | Nijhawan Pardeep | CEO | Buy | 1,000 | $6.60 | $7K | SEC |
| Mar 6, 2026 | Nijhawan Pardeep | CEO | Buy | 10,000 | $3.90 | $39K | SEC |
| Mar 5, 2026 | Nijhawan Pardeep | CEO | Buy | 10,000 | $4.26 | $43K | SEC |
| Mar 4, 2026 | Nijhawan Pardeep | CEO | Buy | 10,000 | $3.63 | $36K | SEC |
| Mar 3, 2026 | Nijhawan Pardeep | CEO | Buy | 1,000 | $2.28 | $2K | SEC |
| Mar 3, 2026 | Nijhawan Pardeep | CEO | Buy | 2,000 | $2.00 | $4K | SEC |
| Mar 2, 2026 | Nijhawan Pardeep | CEO | Buy | 20,571 | $1.58 | $33K | SEC |
| Mar 2, 2026 | Nijhawan Pardeep | CEO | Buy | 30,000 | $2.22 | $67K | SEC |
| Mar 25, 2024 | Nijhawan Pardeep | CEO | Buy | 5,000 | $4.00 | $20K | SEC |
| Jan 11, 2023 | van der Velden Peter | 10% Owner | Sell | 12,895 | $2.63 | $34K | SEC |
| Jan 11, 2023 | van der Velden Peter | 10% Owner | Sell | 12,284 | $2.66 | $33K | SEC |
| Jan 11, 2023 | van der Velden Peter | 10% Owner | Sell | 132,845 | $2.66 | $353K | SEC |
| Jan 11, 2023 | van der Velden Peter | 10% Owner | Sell | 139,450 | $2.63 | $367K | SEC |
In the last 12 months Edesa Biotech, Inc. insiders made open-market purchases worth about $233,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in EDSA was filed on 2026-03-11.
33 investment managers reported holding EDSA in SEC Form 13F filings for Q2 2026.
No congressional trades in EDSA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).